Tag : III

Latest News

Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design

Newsemia
Moreau, P; Dimopoulos, MA; Yong, K; Mikhael, J; Risse, M-L; Asset, G; Martin, T; (2020) Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple...
Latest News

Antithrombin III Testing Market, 2020 – Competitive Strategies, Country Forecasts, Innovative technologies & Instrumentation – ResearchAndMarkets.com

Newsemia
DUBLIN–(BUSINESS WIRE)–The “2020 Antithrombin III Testing Market: USA, Europe, Japan – Competitive Strategies, Country Forecasts, Innovative technologies and Instrumentation” report has been added to ResearchAndMarkets.com’s...
Latest News

Study of the spatial association between an active region jet and a nonthermal type III radio burst

Newsemia
Mulay, SM; Sharma, R; Valori, G; Vasquez, AM; Del Zanna, G; Mason, H; Oberoi, D; (2019) Study of the spatial association between an active region...
Surgery/Cosmetic

Predictors for complete pathological response for stage II and III rectal cancer following neoadjuvant therapy – A systematic review and meta-analysis

Newsemia
There has been an increasing interest in the complete pathological response (pCR) in rectal cancers following neoadjuvant therapy. The aim of this study was to...
Latest News

Samenvatting: Resultaten van Fase III SAkuraSky-studie voor Chugai’s Satralizumab bij Neuromyelitis Optica Spectrumstoornis Gepubliceerd in The New England Journal of Medicine Online

Newsemia
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) heeft aangekondigd dat de resultaten van de SAkuraSky-studie (NCT02028884), een wereldwijde fase III klinische studie van satralizumab (ontwikkelingscode:...
Latest News

Positive Phase III Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in the New England Journal of Medicine

Newsemia
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that data from SAkuraSky, a pivotal Phase...
Latest News

Riassunto: Takeda presenta i dati di 18 mesi dallo studio clinico pivotale di fase III sul candidato vaccino anti-dengue in occasione del 68o Congresso annuale della American Society of Tropical Medicine and Hygiene (ASTMH)

Newsemia
CAMBRIDGE, Massachusetts e OSAKA, Giappone–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502 / NYSE:TAK) (“Takeda”) oggi ha annunciato che i risultati aggiornati dallo studio pivotale di fase...
Latest News

Shionogi riferisce risultati positivi di uno studio di fase III su cefiderocol negli adulti con polmonite nosocomiale causata da agenti patogeni Gram-negativi

Newsemia
AMSTERDAM, Paesi Bassi–(BUSINESS WIRE)–Shionogi & Co., Ltd. (di seguito “Shionogi”) ha reso noti i risultati di APEKS-NP, uno studio clinico internazionale di fase III randomizzato...
Latest News

UCB psoriasis drug beats J&J’s second top-selling product in Phase III study

Newsemia
Results of the BE VIVID study showed that UCB’s bimekizumab showed a statistically significant improvement in skin clearance compared with J&J’s Stelara and placebo. Source...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy